Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2023 | Phase I trial evaluating belantamab mafodotin plus KRd in patients with multiple myeloma

Shebli Atrash, MD, Levine Cancer Institute, Charlotte, NC, discusses the results from a recent Phase I trial (NCT04822337) evaluating the safety and efficacy of belantamab mafodotin in combination with carfilzomib, lenalidomide and dexamethasone (KRd) in patients with multiple myeloma. Dr Atrash elaborates on the safety of the combination and the positive responses observed in patients. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.